Reported Earlier, Dyne Therapeutics Prices $325.5M Public Offering Of 10.5M Common Stock At $31/Share
The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024